Home / Market News / $IRD
benzinga Corporate Catalyst Impact 75/100 ● positive

Opus Genetics Presents Clinical Findings From OPGx-BEST1 And OPGx-LCA5 Gene Therapy Programs At Retina In Rio 2026; Phase 3 Clinical Trial Dosing For OPGx-LCA5 Expected In Q4 Of 2026

Oct 15, 2026, 8:02 PM UTC · Primary ticker $IRD

Opus Genetics presented positive clinical findings for its OPGx-BEST1 and OPGx-LCA5 gene therapy programs, showing improved retinal sensitivity and visual function. The company also announced that Phase 3 clinical trial dosing for OPGx-LCA5 is expected in Q4 2026, indicating significant progress in its drug development pipeline.

Opus Genetics (IRD) announced positive clinical findings from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio 2026. The OPGx-BEST1 program showed improved retinal sensitivity in 75% of evaluable participants in its Phase 1/2 trial, while OPGx-LCA5 demonstrated sustained improvements in visual acuity and light sensitivity in both adult and pediatric participants. This news is a significant positive catalyst for Opus Genetics as it validates their gene therapy platforms and de-risks future development. The announcement of Phase 3 clinical trial dosing for OPGx-LCA5 in Q4 2026 provides a clear timeline for a major milestone, which could lead to substantial long-term value creation if successful. For traders, this presents an opportunity for short-term upside due to increased investor confidence and long-term growth potential, though clinical trial risks always remain.

$IRD positive Positive clinical trial data and advancement to Phase 3
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.